Document Detail

Extranuclear signaling by estrogen: role in breast cancer progression and metastasis.
MedLine Citation:
PMID:  21079578     Owner:  NLM     Status:  MEDLINE    
The estrogen receptor (ERa) is implicated in the progression of breast cancer. Hormonal therapies which block ER functions or local and systemic estrogen production are currently used to treat ERa positive breast cancer. Hormonal therapy shows beneficial effects, however, initial or acquired resistance to endocrine therapies frequently occurs, and tumors recur as metastasis. Emerging evidence suggests in addition to exerting its well-studied nuclear functions, ERa also participates in extranuclear signaling that involve growth factor signaling components, adaptor molecules and the stimulation of cytosolic kinases. ERa extranuclear pathways have the potential to activate gene transcription, modulate cytoskeleton, and promote tumor cell proliferation, survival, and metastasis. Cytoplasmic/membrane ERa is detected in a subset of breast tumors and expression of extranuclear components ERa is deregulated in tumors. The extranuclear actions of ER are emerging as important targets for tumorigenic and metastatic control. Inhibition of ERa extranuclear actions has the potential to prevent breast tumor progression and may be useful in preventing ERa positive metastasis. In this review, we summarize the results of recent research into the role of ERa mediated extranuclear actions in breast tumorigenesis and metastasis.
V Cortez; M Mann; D W Brann; R K Vadlamudi
Related Documents :
21079578 - Extranuclear signaling by estrogen: role in breast cancer progression and metastasis.
10094898 - Primary breast carcinoma of the vulva: a case report and literature review.
16780218 - Assessment of degradation and ubiquitination of cxcr4, a gpcr regulated by egfr family ...
19109168 - Estradiol increases il-8 secretion of normal human breast tissue and breast cancer in v...
8527048 - The first documentation of li-fraumeni syndrome in korea.
25449778 - Circulating tumour cells and lung microvascular tumour cell retention in patients with ...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Minerva ginecologica     Volume:  62     ISSN:  0026-4784     ISO Abbreviation:  Minerva Ginecol     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-11-16     Completed Date:  2011-05-06     Revised Date:  2014-09-12    
Medline Journal Info:
Nlm Unique ID:  0400731     Medline TA:  Minerva Ginecol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  573-83     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents, Hormonal / therapeutic use
Breast Neoplasms / drug therapy,  genetics*,  pathology,  secondary*
Disease Progression
Estrogen Receptor alpha / genetics*
Neoplasm Invasiveness
Neoplasm Metastasis
Receptors, Estrogen / genetics
Signal Transduction / genetics*
Treatment Outcome
Tumor Markers, Biological / genetics
Grant Support
5R01NS050730/NS/NINDS NIH HHS; CA095681/CA/NCI NIH HHS; R01 CA095681/CA/NCI NIH HHS; R01 CA095681-08/CA/NCI NIH HHS; R01 CA095681-08S1/CA/NCI NIH HHS; R01 NS050730/NS/NINDS NIH HHS
Reg. No./Substance:
0/Antineoplastic Agents, Hormonal; 0/Estrogen Receptor alpha; 0/Receptors, Estrogen; 0/Tumor Markers, Biological; 0/estrogen receptor alpha, human

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  MicroRNAs in breast cancer pathogenesis.
Next Document:  Breast cancer during pregnancy: a literature review.